Published in Exp Neurol on March 13, 2009
Hormone replacement therapy and risk for neurodegenerative diseases. Int J Alzheimers Dis (2012) 0.86
Gender differences in Parkinson's disease: focus on plasma α-synuclein. J Neural Transm (Vienna) (2013) 0.82
Gender Differences in Age-Related Striatal Dopamine Depletion in Parkinson's Disease. J Mov Disord (2015) 0.77
Formulations of hormone therapy and risk of Parkinson's disease. Mov Disord (2014) 0.76
Effects of Pinealectomy and Gonadectomy on Olfactory Bulb Dopaminergic Neurons in Rats. Chin Med J (Engl) (2017) 0.75
Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med (2011) 3.95
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Prospective 10-year surveillance of human prion diseases in Japan. Brain (2010) 2.41
Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res (2004) 2.23
Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci (2008) 1.75
Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem (2003) 1.64
Polyneuropathy caused by cobalt-chromium metallosis after total hip replacement. Muscle Nerve (2010) 1.62
A neuropathological study of autosomal-dominant chorea-acanthocytosis with a mutation of VPS13A. Acta Neuropathol (2008) 1.59
Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease. Eur J Nucl Med Mol Imaging (2007) 1.58
Prevalence of spinocerebellar degenerations in the Hokuriku district in Japan. Neuroepidemiology (2009) 1.49
Immunoglobulin light-chain (AL) amyloidosis with myasthenic symptoms and echocardiographic features of dilated cardiomyopathy. Intern Med (2006) 1.46
R-spondin, a novel gene with thrombospondin type 1 domain, was expressed in the dorsal neural tube and affected in Wnts mutants. Biochim Biophys Acta (2004) 1.46
Effect of sample size for normal database on diagnostic performance of brain FDG PET for the detection of Alzheimer's disease using automated image analysis. Nucl Med Commun (2008) 1.42
Rapid scanning protocol for brain (18)F-FDG PET: a validation study. J Nucl Med (2005) 1.41
Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol Aging (2004) 1.36
Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol (2009) 1.30
Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem (2006) 1.27
SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS One (2013) 1.23
REVIEW: Curcumin and Alzheimer's disease. CNS Neurosci Ther (2010) 1.22
Acute encephalitis caused by intrafamilial transmission of enterovirus 71 in adult. Emerg Infect Dis (2008) 1.19
Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro. Biochim Biophys Acta (2004) 1.10
CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res (2008) 1.10
Kinetic modeling and determination of reaction constants of Alzheimer's beta-amyloid fibril extension and dissociation using surface plasmon resonance. Biochemistry (2002) 1.08
Cross-seeding effects of amyloid β-protein and α-synuclein. J Neurochem (2012) 1.08
Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging (2013) 1.07
Phenolic compounds prevent amyloid β-protein oligomerization and synaptic dysfunction by site-specific binding. J Biol Chem (2012) 1.05
Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology (2005) 1.05
Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging (2011) 1.04
Association of an 11-12 kDa protease-resistant prion protein fragment with subtypes of dura graft-associated Creutzfeldt-Jakob disease and other prion diseases. J Gen Virol (2003) 1.03
Myoclonic involuntary movement associated with chronic manganese poisoning. J Neurol Sci (2002) 1.02
Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration. J Alzheimers Dis (2009) 1.01
Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro. Biochem Biophys Res Commun (2005) 1.01
The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta. Curr Pharm Des (2006) 0.99
Low-n oligomers as therapeutic targets of Alzheimer's disease. J Neurochem (2011) 0.98
Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med (2004) 0.98
Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci (2005) 0.98
Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging (2005) 0.97
Brain-targeted proanthocyanidin metabolites for Alzheimer's disease treatment. J Neurosci (2012) 0.97
Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease. Curr Pharm Des (2008) 0.97
Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro. Biol Psychiatry (2002) 0.95
Allodynia in the flank after thalamic stroke. J Clin Neurosci (2006) 0.94
B-cell neurolymphomatosis confined to the peripheral nervous system. J Neurol Sci (2007) 0.94
The anti-amyloidogenic effect is exerted against Alzheimer's beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure. Biochemistry (2007) 0.92
Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. Biochim Biophys Acta (2006) 0.92
Critical role of interfaces and agitation on the nucleation of Abeta amyloid fibrils at low concentrations of Abeta monomers. Biochim Biophys Acta (2010) 0.92
Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. Neuropharmacology (2007) 0.91
Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol (2004) 0.91
Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol (2008) 0.90
Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. J Neurochem (2002) 0.90
Relationships between clinicopathological features and cerebrospinal fluid biomarkers in Japanese patients with genetic prion diseases. PLoS One (2013) 0.90
Medical procedures and risk for sporadic Creutzfeldt-Jakob disease, Japan, 1999-2008. Emerg Infect Dis (2009) 0.90
Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. J Nucl Med (2007) 0.90
Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer's disease. J Alzheimers Dis (2010) 0.90
The risk of iatrogenic Creutzfeldt-Jakob disease through medical and surgical procedures. Neuropathology (2009) 0.90
Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus. J Neurol Sci (2008) 0.88
Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiol Aging (2010) 0.88
Effect of melatonin on α-synuclein self-assembly and cytotoxicity. Neurobiol Aging (2011) 0.88
Peripheral neuropathy associated with chronic natural killer cell lymphocytosis. J Neurol Sci (2005) 0.88
Familial Parkinson disease mutations influence α-synuclein assembly. Neurobiol Dis (2011) 0.87
A linear lesion along the brachial plexus on FDG-PET in neurolymphomatosis. Intern Med (2008) 0.86
Vitamin A has anti-oligomerization effects on amyloid-β in vitro. J Alzheimers Dis (2011) 0.86
Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro. J Neurosci Res (2007) 0.86
Duration of prion disease is longer in Japan than in other countries. J Epidemiol (2011) 0.86
A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic. Dement Geriatr Cogn Disord (2010) 0.86
Vitamin A and Alzheimer's disease. Geriatr Gerontol Int (2011) 0.86
Two different clinical phenotypes of Creutzfeldt-Jakob disease with a M232R substitution. J Neurol (2007) 0.86
Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer's disease brains. Arch Histol Cytol (2007) 0.85
MRI of segmental zoster paresis. Neurology (2005) 0.85
Deciphering the pathogenesis of sporadic Creutzfeldt-Jakob disease with codon 129 M/V and type 2 abnormal prion protein. Acta Neuropathol Commun (2013) 0.85
An autopsy case of an aged patient with spinocerebellar ataxia type 2. Neuropathology (2010) 0.85
Insight into the frequent occurrence of dura mater graft-associated Creutzfeldt-Jakob disease in Japan. J Neurol Neurosurg Psychiatry (2013) 0.85
Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol (2011) 0.85
In vitro differentiation of lineage-negative bone marrow cells into microglia-like cells. Eur J Neurosci (2010) 0.84
The efficacy of radiation monotherapy for Tolosa-Hunt syndrome. J Neurol (2009) 0.84
Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease. J Neurol (2011) 0.84
Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro. Biochem Biophys Res Commun (2005) 0.84
Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases. Exp Neurol (2007) 0.84